Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other primary glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase Ib trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. The company is headquartered in Seattle, Washington.
IPO Year: 2015
Exchange: NASDAQ
Website: chinooktx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/8/2023 | $42.00 | Outperform → Neutral | Wedbush |
| 3/6/2023 | $41.00 | Overweight | Piper Sandler |
| 3/1/2023 | $43.00 | Buy | Guggenheim |
| 12/5/2022 | $30.00 | Overweight | Wells Fargo |
| 6/28/2022 | $30.00 | Buy | Stifel |
SEATTLE, May 09, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ:KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today reported financial results for the first quarter ended March 31, 2023 and provided corporate updates. "During the first quarter of 2023, we continued to advance our pipeline of clinical and preclinical programs for rare, severe chronic kidney diseases. We recently completed full enrollment of the phase 3 ALIGN clinical trial, are on track to initiate the phase 3 BION-1301 IgAN clinical trial mid-year and expect to report topline ALIGN results in the fourth quarter of thi
SEATTLE, April 13, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ:KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced the appointment of Robert W. Azelby to its Board of Directors. Mr. Azelby brings more than 20 years of executive leadership and commercial experience in the biopharmaceutical industry to Chinook. "We are thrilled to welcome Bob to Chinook's board of directors as we advance our pipeline through key milestones in 2023 and beyond," said Eric Dobmeier, president and chief executive officer of Chinook Therapeutics. "Bob brings significant industry experience in bu
SEATTLE, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ:KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced the appointment of Andrew Oxtoby as chief commercial officer. "We are pleased to welcome Andrew to Chinook as we prepare for a year of important milestones for our atrasentan and BION-1301 programs," said Eric Dobmeier, president and chief executive officer of Chinook Therapeutics. "Andrew is an accomplished industry leader with more than 20 years of global biopharmaceutical experience and a proven track record of building commercial strategies and executing n
SEATTLE, March 21, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ:KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced the appointment of Mahesh Krishnan, M.D., M.P.H., M.B.A., FASN to its Board of Directors. Dr. Krishnan, who currently serves as group vice president of research and development at DaVita Inc., brings more than 20 years of practicing nephrology and industry experience to Chinook. "We are pleased to welcome Mahesh to our board as we continue to advance our diversified pipeline of programs for rare, severe chronic kidney diseases," said Eric Dobmeier, president
SEATTLE, Jan. 24, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ:KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced the appointment of Charlotte Jones-Burton, M.D., M.S. as senior vice president of product development and strategy. "We are pleased to welcome Charlotte to Chinook as we continue to advance the clinical development of atrasentan and BION-1301 for IgA nephropathy and prepare to initiate the phase 1 trial of CHK-336 in healthy volunteers for primary hyperoxaluria," said Eric Dobmeier, president and chief executive officer of Chinook Therapeutics. "Charlotte's ex
15-12G - CHINOOK THERAPEUTICS, INC. (0001435049) (Filer)
EFFECT - CHINOOK THERAPEUTICS, INC. (0001435049) (Filer)
S-8 POS - CHINOOK THERAPEUTICS, INC. (0001435049) (Filer)
S-8 POS - CHINOOK THERAPEUTICS, INC. (0001435049) (Filer)
S-8 POS - CHINOOK THERAPEUTICS, INC. (0001435049) (Filer)
S-8 POS - CHINOOK THERAPEUTICS, INC. (0001435049) (Filer)
S-8 POS - CHINOOK THERAPEUTICS, INC. (0001435049) (Filer)
S-8 POS - CHINOOK THERAPEUTICS, INC. (0001435049) (Filer)
S-8 POS - CHINOOK THERAPEUTICS, INC. (0001435049) (Filer)
S-8 POS - CHINOOK THERAPEUTICS, INC. (0001435049) (Filer)
Wedbush downgraded Chinook Therapeutics from Outperform to Neutral and set a new price target of $42.00
Piper Sandler initiated coverage of Chinook Therapeutics with a rating of Overweight and set a new price target of $41.00
Guggenheim initiated coverage of Chinook Therapeutics with a rating of Buy and set a new price target of $43.00
Wells Fargo initiated coverage of Chinook Therapeutics with a rating of Overweight and set a new price target of $30.00
Stifel initiated coverage of Chinook Therapeutics with a rating of Buy and set a new price target of $30.00
SEATTLE, July 28, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ:KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that the first patient with IgA nephropathy (IgAN) has been enrolled in the BEYOND study, a pivotal phase 3 clinical trial evaluating the safety and efficacy of zigakibart (BION-1301), a potentially disease-modifying anti-APRIL monoclonal antibody. "Initiation of the phase 3 BEYOND study is an important step towards our goal of providing an innovative treatment option for patients with IgAN, a disease with high unmet need and limited treatment options," said E
NEW YORK, June 24, 2023 (GLOBE NEWSWIRE) -- Bunge Limited (NYSE:BG) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of BG and Viterra Limited. Under the terms of the agreement, Viterra Limited shareholders will receive approximately 65.6 million shares of BG common stock and $2.0 billion in cash. In addition, BG will assume $9.8 billion of Viterra Limited debt and BG plans to repurchase $2.0 billion of BG common stock. If you are a BG investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-m
CHK-336 was generally well tolerated in healthy volunteers (HV) who received single doses up to 500 mg and multiple doses up to 60 mg for 14 daysPharmacokinetics (PK) was well characterized with dose-proportional exposures and a half-life that supports once-daily dosingSuccessful implementation of a novel 13C2-glycolate tracer established proof-of-mechanism of CHK-336 to block hepatic oxalate production in HVsOne serious adverse event (SAE) of anaphylaxis occurred in a multiple ascending dose HV who received one 125 mg dose CHK-336, resulting in voluntary study pauseAdditional research presented on the impact of maladaptive tubular epithelial cells on progression of chronic kidney disease S
Zigakibart treatment continues to demonstrate rapid and sustained reductions in mechanistic biomarkers, including IgA and Gd-IgA1 levels, which correspond to clinically meaningful proteinuria reductions in patients with IgAN across Cohorts 1 and 2Zigakibart is well-tolerated, with no ADAs observed or treatment discontinuations due to adverse events (AEs) in patients with IgAN across Cohorts 1 and 2 In all patients combined from both Cohorts 1 and 2, zigakibart demonstrated mean proteinuria reductions of 20% at 12 weeks of treatment, 39% at 24 weeks of treatment and 67% at 52 weeks of treatmentExtended treatment with zigakibart resulted in sustained clinical benefit, with 67% mean proteinuria
Novartis to acquire Chinook for $40 per share in cash, with potential to receive up to an additional $4 per share in cash through contingent value rights, for a total equity value of up to approximately $3.5 billionChinook's diversified pipeline of potentially best-in-class programs for rare, severe chronic kidney diseases will significantly expand the Novartis renal portfolio, complementing its existing pipelineTransaction expected to be completed in the second half of 2023, subject to customary closing conditions SEATTLE, June 12, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ:KDNY), a biopharmaceutical company focused on the discovery, development and commercialization
SEATTLE, May 16, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ:KDNY) today announced it has entered a collaboration agreement with Ionis Pharmaceuticals, Inc. for the discovery, development and commercialization of an antisense oligonucleotide (ASO) therapy for a rare, severe chronic kidney disease with significant unmet medical need. The companies will leverage Chinook's precision medicine approach and deep expertise in nephrology and Ionis' extensive expertise in RNA-targeted therapeutics. "We are pleased to collaborate with Ionis on this preclinical discovery program as we continue to strengthen Chinook's position as the leading kidney disease company," said Andrew King
SEATTLE, May 09, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ:KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today reported financial results for the first quarter ended March 31, 2023 and provided corporate updates. "During the first quarter of 2023, we continued to advance our pipeline of clinical and preclinical programs for rare, severe chronic kidney diseases. We recently completed full enrollment of the phase 3 ALIGN clinical trial, are on track to initiate the phase 3 BION-1301 IgAN clinical trial mid-year and expect to report topline ALIGN results in the fourth quarter of thi
SEATTLE, May 05, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ:KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that the Compensation Committee of the Company's Board of Directors approved new employment inducement grants of stock options to purchase a total of 88,000 shares of common stock and restricted stock units for 44,600 shares with a grant date of April 28, 2023 (the "Inducement Grants") for eleven new employees pursuant to the Company's 2022 Equity Inducement Plan. The Inducement Grants have an exercise price per share equal to $20.01, the closing price per shar
Updated interim data to be presented from Cohort 1 and 2 of the ongoing phase 1/2 study of BION-1301 in patients with IgANInitial data to be presented from the phase 1 study of CHK-336 in healthy volunteersAdditional presentations on the design of the phase 2 ASSIST study for atrasentan in patients with IgAN on background RASi and SGLT2i and the phase 3 BEYOND study of BION-1301 in patients with IgAN, as well as research on the impact of maladaptive tubular epithelial cells on disease progression in chronic kidney diseasesChinook to host investor conference call and webcast on June 16, 2023 at 8:15 am EDT to review and discuss the presentations and provide corporate updates SEATTLE, May 05
SEATTLE , April 27, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ:KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook management is scheduled to participate in the following upcoming investor conferences: H.C. Wainwright BioConnect Investor Conference – Fireside chat on Tuesday, May 2nd at 9:30 am EDTBank of America Securities Healthcare Conference 2023 – Fireside chat on Wednesday, May 10th at 2:20 pm EDT To access the audio webcasts and subsequent archived recording of these and other company presentations, please visit the Investors section of Chinook's web
Zigakibart treatment continues to demonstrate rapid and sustained reductions in mechanistic biomarkers, including IgA and Gd-IgA1 levels, which correspond to clinically meaningful proteinuria reductions in patients with IgAN across Cohorts 1 and 2Zigakibart is well-tolerated, with no ADAs observed or treatment discontinuations due to adverse events (AEs) in patients with IgAN across Cohorts 1 and 2 In all patients combined from both Cohorts 1 and 2, zigakibart demonstrated mean proteinuria reductions of 20% at 12 weeks of treatment, 39% at 24 weeks of treatment and 67% at 52 weeks of treatmentExtended treatment with zigakibart resulted in sustained clinical benefit, with 67% mean proteinuria
Updated interim data to be presented from Cohort 1 and 2 of the ongoing phase 1/2 study of BION-1301 in patients with IgANInitial data to be presented from the phase 1 study of CHK-336 in healthy volunteersAdditional presentations on the design of the phase 2 ASSIST study for atrasentan in patients with IgAN on background RASi and SGLT2i and the phase 3 BEYOND study of BION-1301 in patients with IgAN, as well as research on the impact of maladaptive tubular epithelial cells on disease progression in chronic kidney diseasesChinook to host investor conference call and webcast on June 16, 2023 at 8:15 am EDT to review and discuss the presentations and provide corporate updates SEATTLE, May 05
The initial response to de novo subcutaneous (SC) BION-1301 treatment in Cohort 2 is highly consistent with Cohort 1 across both mechanistic biomarkers and proteinuria reductionsBION-1301 is well-tolerated, with no serious adverse events (SAEs) and no treatment discontinuations due to adverse events (AEs) in patients with IgAN across Cohorts 1 and 2BION-1301 continues to demonstrate rapid and sustained reductions in mechanistic biomarkers, including IgA and Gd-IgA1 levels, in patients with IgAN across Cohorts 1 and 2In Cohort 1, BION-1301 demonstrated mean proteinuria reductions of 30.4% at 12 weeks of treatment, 48.8% at 24 weeks of treatment and 66.9% at 52 weeks of treatment, as well as 6
Atrasentan was well-tolerated with no treatment-related serious adverse events (SAEs) Atrasentan demonstrated mean proteinuria reductions of 38.1% proteinuria at six weeks of treatment, 48.3% at 12 weeks of treatment and 54.7% at 24 weeks of treatment There were no meaningful changes in blood pressure or acute eGFR, suggesting proteinuria reductions were not primarily due to hemodynamic effects of atrasentan, and there were no increases in brain natriuretic peptide (BNP) or mean bodyweight, suggesting minimal fluid retention Preclinical data was presented on single-cell RNA-seq of a mouse model of IgAN, revealing a prominent expansion of failed repair proximal tubular epithelial cells, wh
Updated interim data to be presented from the IgA nephropathy (IgAN) patient cohort of the atrasentan phase 2 AFFINITY basket trial Additional interim data to be presented from Cohorts 1 and 2 of the ongoing phase 1/2 study of BION-1301 in patients with IgAN Research presentations include the preclinical efficacy profile of CHK-336 and multiple abstracts detailing Chinook's multidimensional approach to precision medicine in nephrology Chinook to host investor conference call and webcast on November 4, 2022 to review and discuss the abstracts and provide corporate updates SEATTLE, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ:KDNY), a biopharmaceutical company foc
The AFFINITY IgAN cohort of 20 patients is fully enrolled, with 70% of patients in the study having baseline proteinuria over one gram per day despite maximal RAS inhibitor treatment, representing an IgAN patient population at high risk for progressionAtrasentan was well-tolerated with no treatment-related serious adverse events (SAEs)Atrasentan demonstrated 38.0% proteinuria reduction at six weeks of treatment, 49.9% proteinuria reduction at 12 weeks of treatment and 58.5% reduction at 24 weeks of treatmentThere were no meaningful changes in blood pressure or acute eGFR, suggesting proteinuria reductions were not primarily due to hemodynamic effects of atrasentan, and there were no increase
All patients with IgAN in Cohort 1 have transitioned to subcutaneous (SC) dosing, and BION-1301 remains well-tolerated, with no serious adverse events (SAEs) and no treatment discontinuations due to adverse events (AEs)BION-1301 continues to demonstrate rapid and sustained reductions in mechanistic biomarkers in patients with IgAN, including free APRIL, IgA and Gd-IgA1 levelsBION-1301 demonstrated ~50% proteinuria reduction in patients with IgAN after three to six months of treatment, with ~70% reductions observed in six patients at one year and in two patients at 1.5 years of treatmentPreclinical mechanistic data was presented, describing atrasentan's effect to block mesangial cell injury a
SEATTLE, May 12, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ:KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today provided a business update and reported financial results for the first quarter ended March 31, 2022. "During the first quarter of 2022, we made strong progress advancing our pipeline of clinical, research and discovery programs for rare, severe chronic kidney diseases. We continue to enroll patients in the phase 3 ALIGN and phase 2 AFFINITY trials for atrasentan as well as the phase 1/2 trial of BION-1301, and we are pleased to have recently initiated the phase 1 health
Data on atrasentan to be presented in an oral presentation from the IgA nephropathy (IgAN) patient cohort of the phase 2 AFFINITY basket trialUpdated data to be presented from Cohort 1 of Part 3 of the ongoing phase 1/2 study of BION-1301 in patients with IgANAdditional abstracts to be presented include atrasentan's mechanism to block mesangial cell injury and the pathogenic transcriptional networks driving IgAN progression in a translational model, as well as a systems nephrology framework for the molecular classification of chronic kidney disease to fuel Chinook's precision medicine strategy through the Evotec collaborationChinook to host investor conference call and webcast on May 20, 202
BION-1301 was well-tolerated and demonstrated rapid and sustained reductions in mechanistic biomarkers in patients with IgAN, including free APRIL, IgA and Gd-IgA1 levelsBION-1301 demonstrated >50% proteinuria reduction in patients with IgAN after three to six months of treatment, with further reductions in two patients through one year of treatmentAdditional data was presented on the atrasentan program, including translational research demonstrating ETA activation is associated with clinical progression in IgANChinook to host investor conference call and webcast today at 4:30 pm EDT with Jonathan Barratt, MChB, PhD, Mayer Professor of Renal Medicine at University of Leicester, and Laura Koo
4 - CHINOOK THERAPEUTICS, INC. (0001435049) (Issuer)
4 - CHINOOK THERAPEUTICS, INC. (0001435049) (Issuer)
4 - CHINOOK THERAPEUTICS, INC. (0001435049) (Issuer)
4 - CHINOOK THERAPEUTICS, INC. (0001435049) (Issuer)
4 - CHINOOK THERAPEUTICS, INC. (0001435049) (Issuer)
4 - CHINOOK THERAPEUTICS, INC. (0001435049) (Issuer)
4 - CHINOOK THERAPEUTICS, INC. (0001435049) (Issuer)
4 - CHINOOK THERAPEUTICS, INC. (0001435049) (Issuer)
4 - CHINOOK THERAPEUTICS, INC. (0001435049) (Issuer)
4 - CHINOOK THERAPEUTICS, INC. (0001435049) (Issuer)
SC 13D/A - CHINOOK THERAPEUTICS, INC. (0001435049) (Subject)
SC 13D - CHINOOK THERAPEUTICS, INC. (0001435049) (Subject)
SC 13G/A - CHINOOK THERAPEUTICS, INC. (0001435049) (Subject)
SC 13D/A - CHINOOK THERAPEUTICS, INC. (0001435049) (Subject)
SC 13G/A - CHINOOK THERAPEUTICS, INC. (0001435049) (Subject)
SC 13G/A - CHINOOK THERAPEUTICS, INC. (0001435049) (Subject)
SC 13G/A - CHINOOK THERAPEUTICS, INC. (0001435049) (Subject)
SC 13D/A - CHINOOK THERAPEUTICS, INC. (0001435049) (Subject)
SC 13D/A - CHINOOK THERAPEUTICS, INC. (0001435049) (Subject)
SC 13G - CHINOOK THERAPEUTICS, INC. (0001435049) (Subject)
Upgrades JP Morgan upgraded the previous rating for Telephone and Data Systems Inc (NYSE:TDS) from Neutral to Overweight. For the second quarter, Telephone and Data had an EPS of $0.17, compared to year-ago quarter EPS of $0.15. The stock has a 52-week-high of $17.41 and a 52-week-low of $6.43. At the end of the last trading period, Telephone and Data closed at $13.20. JP Morgan upgraded the previous rating for United States Cellular Corp (NYSE:USM) from Neutral to Overweight. United States Cellular earned $0.05 in the second quarter, compared to $0.25 in the year-ago quarter. At the moment, the stock has a 52-week-high of $35.00 and a 52-week-low of $13.79. United States Cellular closed
Wedbush analyst Laura Chico downgrades Chinook Therapeutics (NASDAQ:KDNY) from Outperform to Neutral and announces $42 price target.
Upgrades According to Northcoast Research, the prior rating for Boeing Co (NYSE:BA) was changed from Sell to Neutral. In the second quarter, Boeing showed an EPS of $0.82, compared to $0.37 from the year-ago quarter. At the moment, the stock has a 52-week-high of $240.13 and a 52-week-low of $120.99. Boeing closed at $238.85 at the end of the last trading period. For Varonis Systems Inc (NASDAQ:VRNS), Craig-Hallum upgraded the previous rating of Hold to Buy. Varonis Systems earned $0.01 in the second quarter, compared to $0.00 in the year-ago quarter. The current stock performance of Varonis Systems shows a 52-week-high of $32.05 and a 52-week-low of $15.61. Moreover, at the end of the la
Analysts have provided the following ratings for Chinook Therapeutics (NASDAQ:KDNY) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 2 8 0 0 Last 30D 0 0 1 0 0 1M Ago 0 0 0 0 0 2M Ago 0 0 7 0 0 3M Ago 0 2 0 0 0 These 10 analysts have an average price target of $39.0 versus the current price of Chinook Therapeutics at $39.18, implying downside. Below is a summary of how these 10 analysts rated Chinook Therapeutics over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock Thi
Wells Fargo analyst Mohit Bansal downgrades Chinook Therapeutics (NASDAQ:KDNY) from Overweight to Equal-Weight and raises the price target from $30 to $40.
HC Wainwright & Co. analyst Ed Arce reiterates Chinook Therapeutics (NASDAQ:KDNY) with a Neutral and maintains $40 price target.
Upgrades MoffettNathanson upgraded the previous rating for Shift4 Payments Inc (NYSE:FOUR) from Market Perform to Outperform. For the first quarter, Shift4 Payments had an EPS of $0.51, compared to year-ago quarter EPS of $0.15. The stock has a 52-week-high of $76.40 and a 52-week-low of $29.41. At the end of the last trading period, Shift4 Payments closed at $64.55. According to Roth MKM, the prior rating for Maxeon Solar Technologies Ltd (NASDAQ:MAXN) was changed from Neutral to Buy. In the first quarter, Maxeon Solar Technologies showed an EPS of $0.46, compared to $1.45 from the year-ago quarter. At the moment, the stock has a 52-week-high of $38.91 and a 52-week-low of $10.02. Maxeon
Evercore ISI Group analyst Josh Schimmer downgrades Chinook Therapeutics (NASDAQ:KDNY) from Outperform to In-Line and announces $40 price target.
Upgrades According to Goldman Sachs, the prior rating for Oracle Corp (NYSE:ORCL) was changed from Sell to Neutral. For the fourth quarter, Oracle had an EPS of $1.67, compared to year-ago quarter EPS of $1.54. The current stock performance of Oracle shows a 52-week-high of $117.51 and a 52-week-low of $60.78. Moreover, at the end of the last trading period, the closing price was at $116.43. For BRP Inc (NASDAQ:DOOO), DA Davidson upgraded the previous rating of Neutral to Buy. BRP earned $1.76 in the first quarter, compared to $1.31 in the year-ago quarter. At the moment, the stock has a 52-week-high of $90.42 and a 52-week-low of $58.96. BRP closed at $75.06 at the end of the last tradin